Wang, X;
Bishop, C;
O'Callaghan, J;
Gayhoor, A;
Albani, J;
Theriault, W;
Chappell, M;
... Becerra, L; + view all
(2023)
MRI assessment of cerebral perfusion in clinical trials.
Drug Discovery Today
, 28
(4)
, Article 103506. 10.1016/j.drudis.2023.103506.
Preview |
Text
Golay_DRUDIS-D-22-00181 edited for typesetter.pdf - Accepted Version Download (434kB) | Preview |
Abstract
Neurodegenerative mechanisms affect the brain through a variety of processes that are reflected as changes in brain structure and physiology. Although some biomarkers for these changes are well established, others are at different stages of development for use in clinical trials. One of the most challenging biomarkers to harmonize for clinical trials is cerebral blood flow (CBF). There are several magnetic resonance imaging (MRI) methods for quantifying CBF without the use of contrast agents, in particular arterial spin labeling (ASL) perfusion MRI, which has been increasingly applied in clinical trials. In this review, we present ASL MRI techniques, including strategies for implementation across multiple imaging centers, levels of confidence in assessing disease progression and treatment effects, and details of image analysis.
Archive Staff Only
 |
View Item |
